118
Participants
Start Date
June 21, 2018
Primary Completion Date
August 17, 2021
Study Completion Date
September 2, 2021
Lucerastat
Hard gelatin capsules containing 250 mg of lucerastat and inactive excipients; 1000 mg (4 capsules) twice daily (b.i.d.); dose adjusted for renal function.
Placebo
Placebo capsules are identical in appearance to the lucerastat capsules, and contain inactive excipients; 4 capsules b.i.d.; dose adjusted for renal function.
Allgemeines Krankenhaus der Stadt Wien - Universitätsklinik für Innere Medizin III - Klinische Abteilung für Nephrologie und Dialyse, Vienna
University Hospital Leuven, Leuven
Royal Melbourne Hospital - Department of Nephrology, Parkville
Haukeland University Hospital Helse Bergen HF, Bergen
Royal Perth Hospital, Department of Nephrology, Perth
Universität Zürich Psychiatrische Universitätsklinik, Zurich
University Hospital Ghent, Ghent
Charite Campus Virchow-Klinikum - Nephrologie und Internistische Intensivmedizin, Berlin
Children's Hospital of Pittsburgh (UPMC), Pittsburgh
University of Pennsylvania, Philadelphia
ASST Monza, Hospital San Gerardo, Nephrology, Monza
Lysosomal and Rare Disorders Research and Treatment Center, Fairfax
Hospital Academisch Medisch Centrum - Department of Internal Medicine Div. Endrocrinology and Metabolism, Amsterdam
Duke University Medical Center, Durham
Hospital Universitario Ramon y Cajal. Servicio de Medicina Interna, Madrid
Greenwood Genetic Center, Greenville
Emory University School of Medicine; Department of Human Genetics, Atlanta
University of Florida College of Medicine - Division of Nephrology, Hypertension & Renal Transplantation, Gainesville
University of Alabama at Birmingham - Nephrology Research Clinic, Birmingham
Infusion Associates, Grand Rapids
Hospital Quironsalud Zaragoza, Zaragoza
University of Iowa Stead Family Children's Hospital - Division of Medical Genetics, Iowa City
Rush University Medical Center, Chicago
SphinCS GmbH, Höchheim
Research Baylor Institute of Metabolic Disease, Dallas
Fachinternistische Gemeinschaftspraxis Markgräferland, Mühlheim
University of Naples Federico II (Nephrology), Naples
University of Utah - Division of Medical Genetics, Salt Lake City
University of California Irvine, Irvine
UCSF Benioff Children's Hospital Oakland, Oakland
Medizinische Klinik und Poliklinik I der Universität - Schwerpunkt Nephrologie, Würzburg
Oregon Health and Science University, Portland
Massachusetts General Hospital, Boston
London Health Sciences Centre - Victoria Hospital, London
M.A.G.I.C Clinic Ltd, Calgary
Queen Elizabeth II Health Sciences Center - Halifax Infirmary - Division of Nephrology, Halifax
Research Center, Hôpital Du Sacré-Coeur de Montréal, Montreal
Vancouver Hospital & Health Sciences - Vancouver General Hospital, Vancouver
Health Sciences Center Winnipeg, Winnipeg
Hosp Alma Mater Studiorum, Dublin
University Hospital in Cracow - Dep. of of Allergies and Immunology, Krakow
Cardinal Wyszynski Institute of Cardiology, Warsaw
Department of Pediatric Nutrition and Metabolic Diseases; The Children's Memorial Health Institute, Warsaw
Hospital Universitari Vall d'Hebrón, Barcelona
Hospital Universitari de Bellvitge; Hospitalet de Llobregat, Barcelona
University Hospital Birmingham NHS Foundation Trust - Center for Rare Diseases, Birmingham
The Royal Free Hospital, Department of Haematology Royal Free London NHS Foundation Trust, London
National Hospital for Neurology and Neurosurgery, London
Salford Royal (Hope) Hospital, Salford
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
INDUSTRY